PNC-27

PNC-27 is a synthetic research peptide assembled from two functional segments: a sequence derived from the p53 tumor-suppressor protein (corresponding to a region within its transactivation domain) joined to a membrane-residency / penetrating leader sequence that has been reported to facilitate the peptide's association with cell membranes. It is supplied in lyophilized form for laboratory and professional research use only and is not approved by the FDA for therapeutic use. Within the "Healing & Recovery" catalog grouping, PNC-27 is cataloged primarily as an investigational compound studied in preclinical and cell-based models. This reference entry is intended for licensed practitioners and research purchasers as professional product information, not as patient-directed marketing or a claim of clinical benefit. Any effects or outcomes referenced in the literature are model-dependent, and individual results vary.

• Investigated in preclinical and in vitro literature for its reported interaction with the p53/HDM-2 (MDM2) signaling axis
• Studied in cell-culture models for reported selective association with the membranes of certain transformed cell lines versus non-transformed controls
• Examined in laboratory research as a model peptide for membrane-targeting and pore-related mechanisms under investigation
• Used as a research tool compound for exploring p53-derived peptide structure-activity relationships
• Explored in preclinical settings within broader cellular-recovery and apoptosis-signaling research programs

Supplied as a lyophilized powder for research and professional use. As a general handling reference, lyophilized peptide is commonly reconstituted with bacteriostatic water (or another suitable sterile diluent selected by the purchasing laboratory); the vial is typically swirled gently rather than shaken to dissolve. Store unreconstituted vials cold per supplier documentation (generally refrigerated for short-term and frozen for longer-term storage), keep reconstituted material refrigerated, protect from light, avoid repeated freeze-thaw cycles, and use aseptic technique throughout. This information is provided as general reconstitution, storage, and handling reference only and does not constitute dosing guidance. All clinical and research protocols, including any preparation and administration parameters, are determined solely by the licensed ordering provider, and this entry is reference information, not medical advice.

A per-lot Certificate of Analysis, HPLC purity profile, and mass-spectrometry verification are available on request for this product. Ask your account manager for the current lot documentation.

In the published preclinical literature, PNC-27 is described as combining a p53-derived peptide segment with a membrane-penetrating leader sequence, a design proposed to direct the molecule toward cell membranes. Research reports have investigated a mechanism in which the peptide is described as associating with HDM-2 (MDM2) localized at or near the membrane of certain transformed cells, with some studies proposing formation of transmembrane pores and resulting loss of membrane integrity in those cell models, while reportedly sparing non-transformed cells in the systems tested. These mechanistic descriptions are drawn from cell-based and preclinical research, remain under active investigation, and have not been established as a basis for any therapeutic use; observations are model-dependent and individual results vary.